Left Atrial Appendage Morphology With The Progression of Atrial Fibrillation

Yoichi Takaya (✉ takayayoichi@yahoo.co.jp)

Okayama University Graduate School of Medicine

Rie Nakayama

Okayama University Graduate School of Medicine

Fumi Yokohama

Okayama University Graduate School of Medicine

Norihisa Toh

Okayama University Graduate School of Medicine

Koji Nakagawa

Okayama University Graduate School of Medicine

Masakazu Miyamoto

Okayama University Graduate School of Medicine

Hiroshi Ito

Okayama University Graduate School of Medicine

Research Article

Keywords: Atrial fibrillation, Left atrial appendage, Transcatheter closure, Transesophageal echocardiography

Posted Date: November 15th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-757374/v2>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Left atrial appendage (LAA) size is crucial for determining the indication of transcatheter LAA closure. The aim of this study was to evaluate the differences in LAA morphology according to the types of atrial fibrillation (AF). A total of 340 patients (mean age: 65 ± 15 years) who underwent transesophageal echocardiography (TEE) were included. Patients were classified into non-AF ($n = 105$), paroxysmal AF ($n = 86$), persistent AF ($n = 87$), or long-standing persistent AF ($n = 62$). LAA morphology, including LAA ostial diameter and depth, was assessed using TEE. Patients with long-standing persistent AF had larger LAA ostial diameter and depth, greater LAA lobes, and lower LAA flow velocity. The maximum LAA ostial diameter was 19 ± 4 mm in patients with non-AF, 21 ± 4 mm in patients with paroxysmal AF, 23 ± 5 mm in patients with persistent AF, and 26 ± 5 mm in patients with long-standing persistent AF. LAA ostial diameter was increased by 2 or 3 mm with the progression of AF. LAA ostial diameter was correlated with LA volume index ($r = 0.37$, $p < 0.01$) and the duration of continuous AF ($r = 0.30$, $p < 0.01$), but not with age or the period from the onset of AF. In conclusion, LAA size, which is the determinant for selecting device size of transcatheter LAA closure, was increased with the progression of AF. Our findings have potential implications for therapeutic strategy of transcatheter LAA closure.

Introduction

Atrial fibrillation (AF) is caused by left atrial (LA) dilatation. The presence of AF further promotes LA remodeling, leading to LA enlargement. LA dilatation is enhanced by the progression of AF [1]. Patients with AF are at increased risk of cardioembolic stroke [2]. LA appendage (LAA), which is a finger-like extension of the left atrium with various morphologies, is the origin of embolism in more than 90% of patients with AF [3]. Recently, transcatheter closure of LAA with the Watchman device (Boston Scientific, Marlborough, Massachusetts, USA) has been proposed as an effective therapy for prevention of embolization [4]. The assessments of LAA morphology using transesophageal echocardiography (TEE) are crucial for determining the indication of transcatheter LAA closure. LAA size has been reported to be increased in patients with AF [5–7]. However, the relationships of LAA size with the types of AF have not been well investigated. The aim of this study was to evaluate the differences in LAA morphology according to the types of AF.

Methods

Study population

A total of 340 consecutive patients who underwent TEE in our institution from October 2019 to October 2020 were included. Patients were classified into non-AF, paroxysmal AF defined as continuous AF for <7 days in duration, persistent AF defined as continuous AF for ≥ 7 days and <1 year in duration, or long-standing persistent AF defined as continuous AF for ≥ 1 year in duration. All patients provided written informed consent for examination. This study was in accordance with the Declaration of Helsinki and approved by the ethics committee of Okayama University Hospital.

Transesophageal Echocardiography Assessments

TEE (iE33 with an X7-2t probe; Philips Medical Systems, Best, The Netherlands) was performed by experienced cardiologists. All images were digitally stored. TEE images of LAA were obtained at an angle of 0°, 45°, 90°, and 135° views, based on the strategy of transcatheter LAA closure with the Watchman device. LAA ostial diameter was measured in each view from the level of the circumflex artery to the appropriate location of the device implantation along the coumadin ridge. LAA depth was measured in each view from the ostium to the tip of LAA [8] (Fig. 1). The maximum LAA ostial diameter and depth among TEE views of 0°, 45°, 90°, and 135° were then selected. The shape of LAA and the number of LAA lobes were assessed by sweeping from 0° to 180°. The shape of LAA was classified into chicken wing or non-chicken wing, including windsock, cauliflower, and cactus [9]. LAA flow velocity was measured with pulsed wave Doppler imaging in the proximal third of the appendage.

Clinical Assessments

CHA₂DS₂-VASc (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, age 65-74 years, sex category) and HAS-BLED (hypertension, abnormal renal or liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs or alcohol) scores were calculated. The duration of continuous AF and the period from the onset of AF were estimated by symptoms and electrocardiographic findings. For example, in a case of paroxysmal AF which continued for several days from one year ago, we determined that the duration of continuous AF was several days and the period from the onset of AF was one year. Transthoracic echocardiography was performed before TEE examination. Left ventricular (LV) end-diastolic and end-systolic diameters, LV ejection fraction, LA diameter, LA volume index, early diastolic mitral valve flow velocity (E), early diastolic septal mitral annular velocity (e'), the degrees of mitral regurgitation (MR) and tricuspid regurgitation (TR), and TR pressure gradient were obtained. LA diameter was measured at end-ventricular systole on the parasternal long-axis view. LA volume was derived using the biplane Simpson's technique on the apical four-chamber and two-chamber views, and was normalized for body surface area.

Statistical analysis

Continuous variables are presented as mean ± standard deviation. Categorical variables are presented as number and percentage. Differences between groups were analyzed using the 1-way ANOVA for continuous variables and using the χ^2 test or the Fisher exact test for categorical variables. Pearson's correlation coefficient was used to assess correlations between variables. Statistical analysis was performed with JMP version 14.0 (SAS Institute Inc., Cary, NC, USA), and significance was defined as a p value of < 0.05.

Interobserver and intraobserver differences were analyzed among 50 randomly selected cases. LAA ostial diameter was measured by two blinded observers and by a single observer at two different times. Reliability was calculated using Pearson's correlation coefficient. Variability was calculated as the percentage error of each measurement and derived as the difference between the measurements divided by the mean value.

Results

Patient characteristics

The mean age of all patients was 65 ± 15 years, and 206 patients were male. Patient characteristics and transthoracic echocardiographic parameters are shown in Table 1. One hundred five patients had non-AF, 86 had paroxysmal AF, 87 had persistent AF, and 62 had long-standing persistent AF. Patients with long-standing persistent AF had larger LA dilatation and LA volume index, higher E/e' ratio, and moderate-to-severe MR and TR more frequently. CHA₂DS₂-VASc and HAS-BLED scores were higher in patients with long-standing persistent AF.

Table 1
Patient characteristics and transthoracic echocardiographic parameters

	Non- AF (n = 105)	Paroxysmal AF (n = 86)	Persistent AF (n = 87)	Long-standing persistent AF (n = 62)	p
Age (years)	57 ± 17	69 ± 11	68 ± 12	70 ± 11	< 0.01
Male	56 (53%)	50 (58%)	56 (64%)	44 (71%)	0.12
Body surface area (m ²)	1.6 ± 0.2	1.6 ± 0.2	1.7 ± 0.2	1.6 ± 0.2	0.17
CHA ₂ D ₂ -VASc score	1.7 ± 1.7	2.8 ± 1.5	3.3 ± 1.8	3.8 ± 2.0	< 0.01
HAS-BLED score	0.6 ± 0.8	1.4 ± 1.1	1.2 ± 0.9	1.7 ± 1.3	< 0.01
LV end-diastolic diameter (mm)	45 ± 7	47 ± 8	47 ± 7	47 ± 6	0.12
LV end-systolic diameter (mm)	29 ± 6	32 ± 8	33 ± 8	33 ± 7	< 0.01
LV ejection fraction (%)	64 ± 7	60 ± 12	56 ± 13	56 ± 12	< 0.01
LA diameter (mm)	37 ± 6	40 ± 6	45 ± 5	46 ± 7	< 0.01
LA volume index (ml/m ²)	38 ± 14	41 ± 10	52 ± 16	60 ± 18	< 0.01
E (cm/s)	67 ± 22	68 ± 20	83 ± 25	92 ± 35	< 0.01
e' (cm/s)	7 ± 3	5 ± 2	7 ± 2	6 ± 2	< 0.01
E/e' ratio	11 ± 7	14 ± 6	14 ± 7	17 ± 9	< 0.01
Moderate-to-severe MR	10 (10%)	7 (8%)	23 (26%)	19 (31%)	< 0.01
Moderate-to-severe TR	13 (12%)	10 (12%)	20 (23%)	17 (27%)	0.02
TR pressure gradient (mm Hg)	27 ± 16	25 ± 7	26 ± 9	29 ± 10	0.22

	Non-AF	Paroxysmal AF	Persistent AF	Long-standing persistent AF	p
	(n = 105)	(n = 86)	(n = 87)	(n = 62)	
<i>AF</i> atrial fibrillation, <i>CHA₂D₂-VASc</i> congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism, vascular disease, age 65-74 years, sex category, <i>E</i> early diastolic mitral valve flow velocity, <i>e'</i> early diastolic septal mitral annular velocity, <i>HAS-BLED</i> hypertension, abnormal renal or liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs or alcohol, <i>LA</i> left atrial, <i>LV</i> left ventricular, <i>MR</i> mitral regurgitation, <i>TR</i> tricuspid regurgitation					

Left Atrial Appendage Morphology

LAA ostial diameter and depth according to the types of AF are shown in Table 2. In TEE views of an angle of 0°, 45°, 90°, and 135°, LAA ostial diameter and depth were larger in patients with long-standing persistent AF. The maximum LAA ostial diameter measured in any TEE views of 0°, 45°, 90°, or 135° was 19 ± 4 mm in patients with non-AF, 21 ± 4 mm in patients with paroxysmal AF, 23 ± 5 mm in patients with persistent AF, and 26 ± 5 mm in patients with long-standing persistent AF. LAA ostial diameter was increased by 2 or 3 mm with the progression of AF. Patients with long-standing persistent AF had greater LAA lobes and lower LAA flow velocity. LAA shape was not different in the types of AF.

Table 2
Left atrial appendage morphology according to the types of atrial fibrillation.

	Non-AF (n = 105)	Paroxysmal AF (n = 86)	Persistent AF (n = 87)	Long-standing persistent AF (n = 62)	p
LAA ostial diameter (mm)					
0°	16 ± 5	18 ± 4	20 ± 5	22 ± 5	< 0.01
45°	15 ± 4	17 ± 4	19 ± 4	21 ± 4	< 0.01
90°	15 ± 4	17 ± 4	19 ± 4	22 ± 4	< 0.01
135°	18 ± 4	20 ± 5	22 ± 5	25 ± 5	< 0.01
Maximum	19 ± 4	21 ± 4	23 ± 5	26 ± 5	< 0.01
LAA depth (mm)					
0°	24 ± 5	28 ± 6	30 ± 7	30 ± 7	< 0.01
45°	25 ± 5	28 ± 6	29 ± 6	31 ± 6	< 0.01
90°	24 ± 6	27 ± 6	29 ± 6	31 ± 7	< 0.01
135°	23 ± 5	27 ± 6	29 ± 7	31 ± 7	< 0.01
Maximum	27 ± 8	30 ± 6	33 ± 6	34 ± 7	< 0.01
LAA shape					
Chicken wing	27 (26%)	21 (24%)	15 (17%)	10 (16%)	0.31
Non-chicken wing	78 (74%)	65 (76%)	72 (83%)	52 (84%)	
LAA lobes	1.2 ± 0.5	1.6 ± 0.7	1.8 ± 0.6	1.9 ± 0.8	< 0.01
LAA flow velocity (m/s)	58 ± 20	50 ± 19	32 ± 19	26 ± 15	< 0.01
AF atrial fibrillation, LAA left atrial appendage					

Correlation With Left Atrial Appendage Size

Among patients with paroxysmal AF, persistent AF, and long-standing persistent AF, LAA ostial diameter ($r = 0.37$, $p < 0.01$) and LAA depth ($r = 0.44$, $p < 0.01$) were correlated with LA volume index. LAA ostial diameter was correlated with the duration of continuous AF ($r = 0.30$, $p < 0.01$) (Fig. 2), but not with age or the period from the onset of AF. The correlations of LAA ostial diameter with CHA₂D₂-VASc or HAS-BLED scores were not observed.

Variability

There was good agreement in the measurements of LAA ostial diameter in the interobserver assessment ($r = 0.92$, $p < 0.01$) and intraobserver assessment ($r = 0.93$, $p < 0.01$). The interobserver and intraobserver variabilities in LAA ostial diameter were 4.9% and 4.3%, respectively.

Discussion

AF is the most common cardiac arrhythmia, which increases in prevalence by aging. LA dilatation is well known to be related to an increase in burden of AF [1]. Regarding LAA, some studies reported that LAA size was larger in patients with persistent AF [5–7]. One study reported a progressive increase in LAA orifice area with increasing frequency of AF [10]. However, whether LAA morphology, including LAA ostial diameter and depth, is affected by the progression of AF (non-AF, paroxysmal AF, persistent AF, long-standing persistent AF) remains unclear.

The present study evaluated the differences in LAA morphology according to the types of AF and showed that patients with long-standing persistent AF had larger LAA ostial diameter and depth and greater LAA lobes. LAA ostial diameter was increased with the progression of AF (from non-AF to long-standing persistent AF), and was correlated with the duration of continuous AF. LAA has higher compliance compared with LA wall. LAA assists with the adjustability of LA pressure [11]. Therefore, elevated LA pressure due to the persistence of AF may cause the enlargement of LAA ostial diameter [12, 13]. Additionally, LAA ostial diameter was correlated with LA volume, indicating that LA dilatation may also stretch LAA ostial diameter.

LAA is a site of thrombus formation. LAA removal or occlusion is performed to reduce the risk of stroke in patients with AF undergoing open heart surgery [14]. Recently, the effectiveness of transcatheter closure of LAA with the occlusion device has been demonstrated in patients with AF ineligible to anticoagulation therapy. With the advent of transcatheter LAA closure, LAA morphology has become the focus of increasing interest. To implant the occlusion device, such as the Watchman device, LAA ostial diameter and depth are important for selecting the appropriate device size. The present study showed that the maximum LAA ostial diameter was increased by 2 or 3 mm as AF progressed. This result indicates that a larger sized device is required in patients with persistent and long-standing persistent AF.

Several studies have reported that large LAA size is at risk of stroke [15, 16]. The increased number of LAA lobes has been reported to be associated with thrombus formation [17]. The reduced LAA flow velocity is established to be related to an increased risk of thrombus formation [18, 19]. In this study, patients with persistent and long-standing persistent AF had larger LAA size, greater LAA lobes, and lower LAA flow velocity. Therefore, transcatheter LAA closure may have greater benefits for patients with persistent and long-standing persistent AF. However, the currently available device sizes are limited. Some of these patients may not meet the indication of transcatheter LAA closure because of oversized LAA ostial diameter. Furthermore, the use of undersized device may result in incomplete sealing and residual leaks, which lead to intra-LAA thrombus formation and subsequent cardioembolic stroke [20]. These findings suggest that transcatheter LAA closure should be performed at the point when physicians determine the necessity for the treatment. If the decision is delayed, the opportunity for the treatment may be missed due to LAA enlargement. The present study provides meaningful information for performing transcatheter LAA closure in patients with AF.

The present study has several limitations. First, the number of patients was relatively small. Larger study population is needed to confirm our findings. Second, this study included patients who underwent TEE. Patients with non-AF were not healthy subjects. Third, the duration of continuous AF might be underestimated because AF is a disease of partially silent nature. Finally, LAA morphology was not assessed by 3-dimensional TEE. However, the measurement of LAA size with 2-dimensional TEE is recommended for selecting device size of transcatheter LAA closure.

In conclusion, LAA size, which is the determinant for selecting device size of transcatheter LAA closure, was increased with the progression of AF. LAA ostial diameter was correlated with the duration of continuous AF. Our findings have potential implications for therapeutic strategy of transcatheter LAA closure in patients with AF.

Declarations

Funding: The authors received no financial support.

Conflicts of interest: The authors have no relationships relevant to the contents of this paper to disclose.

Availability of data: This study is based on data from our institution. The data are available from the corresponding author on reasonable request.

Code availability: Not required.

Authors' contributions: All authors contributed to the collection of data, discussion and interpretation of the data, and the writing of the report. All authors reviewed and approved the manuscript for submission. The study was designed by YT, KN, MM, and HI. The analysis was performed by YT, RN, FY, and NT. The manuscript was written by YT.

Ethics approval: This study was approved by the ethical committee of our institution.

Consent to participate: Informed consent was obtained before entering this study.

Consent for publication: Not required.

References

1. Delgado V, Di Biase L, Leung M, Romero J, Tops LF, Casadei B, Marrouche N, Bax J (2017) Structure and function of the left atrium and left atrial appendage: AF and stroke implications. *J Am Coll Cardiol* 70:3157–3172
2. Wolf PA, Abbou RD, Kannel WB (1991) Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. *Stroke* 22:983–988
3. Stoddard MF, Dawkins PR, Prince CR, Ammash NM (1995) Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. *J Am Coll Cardiol* 25:452–459
4. Reddy VY, Doshi SK, Kar S, Gibson DN, Price MJ, Huber K, Horton RP, Buchbinder M, Neuzil P, Gordon NT, Holmes DR Jr (2017) 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. *J Am Coll Cardiol* 70:2964–2975
5. Walker DT, Humphries JA, Phillips KP (2012) Anatomical analysis of the left atrial appendage using segmented, three-dimensional cardiac CT: a comparison of patients with paradoxysmal and persistent forms of atrial fibrillation. *J Interv Card Electrophysiol* 34:173–179
6. Glassy MS, Wung W, Westcott S, Smith TWR, Fan D, Rogers JH, Singh GD (2019) Watchman occlusion in long-standing persistent atrial fibrillation. *JACC Cardiovasc Interv* 12:1018–1026
7. Park HC, Shin J, Ban JE, Choi J, Park SW, Kim YH (2013) Left atrial appendage: morphology and function in patients with paroxysmal and persistent atrial fibrillation. *Int J Cardiovasc Imaging* 29:935–944
8. Asmarats L, Rodes-Cabau L (2017) Percutaneous left atrial appendage closure. Current devices and clinical outcomes. *Circ Cardiovasc Interv* 10:e005359
9. Di Biase L, Santangeli P, Anselmino M, Mohanty P, Salvetti I, Gili S, Horton R, Sanchez JE, Bai R, Mohanty S, Pump A, Cereceda Brantes M, Gallinghouse GJ, Burkhardt JD, Cesarani F, Scaglione M, Natale A, Gaita F (2012) Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. *J Am Coll Cardiol* 60:531–538
10. Nucifora G, Faletra FF, Regoli F, Pasotti E, Pedrazzini G, Moccetti T, Auticchio A (2011) Evaluation of the left atrial appendage with real-time 3-dimensional transesophageal echocardiography: implications for catheter-based left atrial appendage closure. *Circ Cardiovasc Imaging* 4:514–523
11. Ito T, Suwa M, Kobashi A, Yagi H, Hirota Y, Kawamura K (1998) Influence of altered loading conditions on left atrial appendage function in vivo. *Am J Cardiol* 81:1056–1059
12. Tabata T, Oki T, Yamada H, Abe M, Onose Y, Thomas JD (2000) Relationship between left atrial appendage function and plasma concentration of atrial natriuretic peptide. *Eur J Echocardiogr* 1:130–137

13. Yoshida K, Ulfarsson M, Oral H, Crawford T, Good E, Jong-narangsinn K, Bogun F, Pelosi F, Jalife J, Morady F, Chugh A (2011) Left atrial pressure and dominant frequency of atrial fibrillation in humans. *Heart rhythm* 8:181–187
14. Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, Cybulsky I, Abouzahr L, Sawchuck C, Carroll S, Morillo C, Kleine P, Chu V, Lonn E, Connolly SJ (2005) Left atrial appendage occlusion study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. *Am Heart J* 150:288–293
15. Beinart R, Heist EK, Newell JB, Holmvang G, Ruskin JN, Mansour M (2011) Left atrial appendage dimensions predict the risk of stroke/TIA in patients with atrial fibrillation. *J Cardiovasc Electrophysiol* 22:10–15
16. Burrell LD, Horne BD, Anderson JL, Muhlestein JB, Whisenant BK (2013) Usefulness of left atrial appendage volume as a predictor of embolic stroke in patients with atrial fibrillation. *Am J Cardiol* 112:1148–1152
17. Yamamoto M, Seo Y, Kawamatsu N, Sato K, Sugano A, Machino-Ohtsuka T, Kawamura R, Nakajima H, Igarashi M, Sekiguchi Y, Ishizu T, Aonuma K (2014) Complex left atrial appendage morphology and left atrial appendage thrombus formation in patients with atrial fibrillation. *Circ Cardiovasc Imaging* 7:337–343
18. Fatkin D, Kelly RP, Feneley MP (1994) Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. *J Am Coll Cardiol* 23:599–607
19. Petersen M, Roehrich A, Balzer J, Shin DI, Meyer C, Kelm M, Kehmeier ES (2015) Left atrial appendage morphology is closely associated with specific echocardiographic flow pattern in patients with atrial fibrillation. *Europace* 17:539–545
20. Holmes DR Jr, Schwartz RS, Latus GG, Van Tassel RA (2018) A history of left atrial appendage occlusion. *Interv Cardiol Clin* 7:143–150

Figures

Figure 1

Transesophageal echocardiography measurement of left atrial appendage size Left atrial appendage ostial diameter and depth were measured at 0°, 45°, 90°, and 135°.

Figure 2

Relationships of left atrial appendage ostial diameter with left atrial volume index (A) and the duration of continuous atrial fibrillation (B). AF atrial fibrillation, LA left atrial, LAA left atrial appendage